Salim Yusuf
Salim Yusuf
Population Health Research Institute, McMaster University and Hamilton Health Sciences
Verified email at mcmaster.ca - Homepage
Title
Cited by
Cited by
Year
Executive summary: heart disease and stroke statistics—2014 update: a report from the American Heart Association
AS Go, D Mozaffarian, VL Roger, EJ Benjamin, JD Berry, MJ Blaha, S Dai, ...
Circulation 129 (3), 399-410, 2014
25433*2014
Executive summary: heart disease and stroke statistics—2015 update: a report from the American Heart Association
D Mozaffarian, EJ Benjamin, AS Go, DK Arnett, MJ Blaha, M Cushman, ...
Circulation 131 (4), 434-441, 2015
150642015
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study
S Yusuf, S Hawken, S ‘unpuu, T Dans, A Avezum, F Lanas, M McQueen, ...
The lancet 364 (9438), 937-952, 2004
137132004
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
Antithrombotic Trialists' Collaboration
Bmj 324 (7329), 71-86, 2002
11930*2002
Dabigatran versus warfarin in patients with atrial fibrillation
SJ Connolly, MD Ezekowitz, S Yusuf, J Eikelboom, J Oldgren, A Parekh, ...
New England Journal of Medicine 361 (12), 1139-1151, 2009
114562009
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation
Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators
New England Journal of Medicine 345 (7), 494-502, 2001
77042001
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.
S Yusuf, P Sleight, J Pogue, J Bosch, R Davies, G Dagenais, ...
The New England journal of medicine 342 (3), 145, 2000
76292000
2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation Developed†…
Authors/Task Force Members, AJ Camm, GYH Lip, R De Caterina, ...
European heart journal 33 (21), 2719-2747, 2012
58832012
Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization
S Yusuf, S Reddy, S ‘unpuu, S Anand
Circulation 104 (22), 2746-2753, 2001
4469*2001
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study
SR Mehta, S Yusuf, RJG Peters, ME Bertrand, BS Lewis, MK Natarajan, ...
The Lancet 358 (9281), 527-533, 2001
41022001
Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions
SOLVD Investigators*
New England Journal of Medicine 327 (10), 685-691, 1992
38981992
Beta blockade during and after myocardial infarction: an overview of the randomized trials
S Yusuf, R Peto, J Lewis, R Collins, P Sleight
Progress in cardiovascular diseases 27 (5), 335-371, 1985
37641985
Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy
Heart Outcomes Prevention Evaluation (HOPE) Study Investigators
The lancet 355 (9200), 253-259, 2000
35722000
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
M Flather
The Lancet 376 (9753), 1670-1681, 2010
33542010
Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case-control study
S Yusuf, S Hawken, S Ounpuu, L Bautista, MG Franzosi, P Commerford, ...
The Lancet 366 (9497), 1640-1649, 2005
33042005
Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study
MJ O'donnell, D Xavier, L Liu, H Zhang, SL Chin, P Rao-Melacini, ...
The Lancet 376 (9735), 112-123, 2010
31502010
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial
S Yusuf, MA Pfeffer, K Swedberg, CB Granger, P Held, JJV McMurray, ...
The Lancet 362 (9386), 777-781, 2003
29962003
The effect of digoxin on mortality and morbidity in patients with heart failure
Digitalis Investigation Group
New England Journal of Medicine 336 (8), 525-533, 1997
29931997
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events†…
HG Site
Lancet 367 (9526), 1903-1912, 2006
2830*2006
Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals
HC Gerstein, JFE Mann, Q Yi, B Zinman, SF Dinneen, B Hoogwerf, ...
Jama 286 (4), 421-426, 2001
27832001
The system can't perform the operation now. Try again later.
Articles 1–20